Renatech Inc. (Headquarters: Isehara City, Kanagawa Prefecture), which builds health indicators based on trace elements and applies them to real-world situations, is pleased to announce that the "Metallo-Balance Test," a screening test developed and provided by the company to assess the risk of cancer and MCI (Mild Cognitive Impairment), will commence on September 10, 2026 (Thu) at Kida Internal Medicine Clinic (Yonezawa City, Yamagata Prefecture). This marks the first introduction of the test in Yamagata Prefecture.

With the addition of this clinic, the accessibility of the "Metallo-Balance Test" in Yonezawa City and surrounding areas of Yamagata Prefecture will be further expanded, offering local residents a more convenient and new option for health management.

Our company will continue to partner with medical institutions nationwide to encourage more people to take an interest in their health status and to provide opportunities to review their daily health management and lifestyle habits as a preventive measure against illness.

What is the Metallo-Balance (MB) Test?

This is a risk screening (sorting) test that objectively assesses the risk of cancer and MCI (Mild Cognitive Impairment) at the time of blood collection by analyzing the concentration balance of 17 types of trace elements (metal elements) in the blood.

【Features of this Test】

Just one 6mL blood draw: Blood is collected safely under appropriate management systems at medical institutions. The test takes approximately 15 minutes, is short, and is reassuring with minimal physical burden.

Site-specific "Cancer Risk Test": A single blood draw evaluates the risk of the following cancers by site (6 sites for men, 9 sites for women) and scores them on a 4-level scale from A to D. [Men] Lung cancer, stomach cancer, liver cancer, pancreatic cancer, colorectal cancer, prostate cancer [Women] Lung cancer, stomach cancer, liver cancer, pancreatic cancer, colorectal cancer, breast cancer, cervical cancer, uterine body cancer, ovarian cancer

Comprehensive "Cognitive Risk Test (MCI Risk Assessment)": This test comprehensively evaluates all types of cognitive decline, not just Alzheimer's type, but also vascular dementia, Lewy body dementia, and others.

Proven Research Results and International Recognition: Developed with research grants from the Ministry of Economy, Trade and Industry's Go-Tech project and through joint research with Kanagawa Cancer Center and Chiba Cancer Center. Patents have been obtained in 9 countries worldwide, including Japan, and the cumulative number of test takers has surpassed 100,000 (results from April 2019 to March 2026).

Test Procedure and Important Precautions Before Taking the Test

*Due to the need for mail-in procedures, advance application is required approximately 3 weeks before the desired test date (reservations are strictly by appointment only).

Application: Please apply via web or phone. Approximately one week before your reservation date, a set of test documents will be delivered to your home.

Test Day (Blood Collection): As reservations are strictly by appointment, blood collection will proceed smoothly (approx. 15 minutes). Payment is made later, so no payment is required at the clinic on the day of the test.

Result Notification: An invoice (payment slip) will be mailed to your home approximately 3 weeks after blood collection, and the test results will be mailed approximately 5 weeks later.

【Important Precautions Before Taking the Test】

Food and Drink: No food or drink is allowed from 9:00 PM the day before. No alcohol is allowed from the day before. Water: Please drink plenty of water to facilitate blood collection.

Medication/Supplements: Over-the-counter medications and supplements are not allowed from the day before. Prescription medications should be taken as usual.

Test Fees (Out-of-Pocket Payment)

This test is not covered by health insurance and is an out-of-pocket expense. You can choose from the following courses according to your needs.

Cancer Risk Test: ¥19,800 (tax included)

Cognitive Risk Test: ¥19,800 (tax included)

Cancer and Cognitive Risk Test Set: ¥24,200 (tax included)

*Prices shown are standard prices. *Payment will be made via "DSK Post-Payment" delivered to your home after blood collection. *Some medical institutions may not offer one of these tests.

Target Individuals and Precautions for the Metallo-Balance Test

【Regarding Target Age】

Cancer Risk Test: Japanese individuals aged 20 to 80

Cognitive Risk Test: Japanese individuals aged 50 to 80

*This test was developed based on data from Japanese individuals within the above age ranges. Therefore, while individuals outside these age ranges or foreign nationals can take the test, the results will be considered "reference values" only. Please be aware of this in advance.

【The following individuals cannot take the test】

Individuals who are pregnant or within 6 months postpartum.

Individuals undergoing cancer treatment or who have completed cancer treatment less than 1 year ago.

Individuals undergoing dialysis.

Individuals with fractures, blood disorders, or immunodeficiency (excluding dyslipidemia due to high triglycerides, etc.).

Individuals who are unwell (e.g., sleep-deprived, after staying up all night, immediately after intense exercise, under severe stress, or experiencing symptoms such as colds, asthma, shingles, allergic rash/rhinitis).

Overview of New Introducing Medical Institution

Test Start Date: September 10, 2026 (Thu) Test Hours: Monday, Tuesday, Thursday, Friday (excluding holidays and public holidays)

Medical Institution Name: Kida Internal Medicine Clinic

Address: 6-4-1 Kanai, Yonezawa City, Yamagata Prefecture, 992-0012 🅿️Parking Available 📍MAP

Access: ● City Loop Bus, etc.: Get off at City Hall Mae, walk north for approx. 10 minutes. Get off at Yonchuu Mae, walk south for approx. 10 minutes. ● Approx. 10 minutes by car from Yonezawa Station. ● Approx. 2 minutes by car north from Yonezawa City Hall. ● Near the Okitama General Government Building, next to Kutsu Ryuutsu Center.

Tests Offered: Cancer Risk Test, Cognitive Risk Test

⚠️ Important Request Regarding Test Taking (Please Read Carefully) Refrain from contacting the medical institution directly: The hospital reception or phone cannot handle inquiries or applications for this test. Please contact Renatech for any questions or applications regarding the test.

For details about the test and to apply, please click here.

Metallo-Balance Test Information Site: https://www.mbkensa.com/

Dedicated Toll-Free Number: 0120-785-602 (Renatech: Weekdays 9:00 AM - 5:00 PM)

▼ Digital Brochure of Metallo-Balance Test

d182526-10-66e3668e1a0ed316840edfc9fa0e1d27.pdf

🏥 Seeking Partner Medical Institutions Nationwide! For inquiries about introducing the Metallo-Balance Test, click here.

Metallo-Balance Original Character: Metarona-chan

Renatech Inc. is an innovation company that develops unique technologies in the medical and health fields, as well as the environmental field, aiming for early risk assessment of diseases such as cancer. The company has also been selected as one of the "300 Excellent Companies of SMEs/Small Businesses that Shine" by the Ministry of Economy, Trade and Industry and the Small and Medium Enterprise Agency, recognizing its excellent technological development and service provision, and its high technical capabilities and social contributions are acknowledged by the government.

Among these, the "Metallo-Balance Test" is attracting significant attention as a groundbreaking screening technology that analyzes the concentration of 17 types of trace elements in the blood to assess the risk of developing cancer and MCI (Mild Cognitive Impairment). Moving forward, Renatech will continue to create new value for the promotion of people's health and the resolution of social issues based on its advanced technological capabilities.

Company Overview ■

Company Name: Renatech Inc.

Representative: Kei Kato, Representative Director

Head Office Location: 4-19-15 Takamori, Isehara City, Kanagawa Prefecture, 259-1114

URL: https://www.renatech.net/

FACT BOX

  • Source: PR TIMES
  • Category: サービス開始